Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical programs, particularly in dermatology and respiratory diseases, while reporting a net loss for the first quarter of 2026, reflecting ongoing investments in drug development and manufacturing [1][5]. Financial Performance - Total operating expenses increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year [4]. - Edesa reported a net loss of $2.2 million, or $0.28 per common share, for the quarter ended December 31, 2025, compared to a net loss of $1.6 million, or $0.48 per common share, for the same quarter in 2024 [5][13]. - Cash and cash equivalents at December 31, 2025, were $12.1 million, with working capital of $12.0 million [6]. Drug Development Progress - Edesa is progressing with the manufacturing of its dermatology drug candidate, EB06, for a Phase 2 study in moderate-to-severe nonsegmental vitiligo, with recruitment expected to begin midyear 2026, pending regulatory approvals [2][3]. - The company is evaluating subgroup data for additional efficacy signals in its respiratory program following positive results from a Phase 3 study of paridiprubart in patients with Acute Respiratory Distress Syndrome [2][3]. Research and Development - Research and development expenses increased by $0.1 million to $1.1 million for the three months ended December 31, 2025, primarily due to increased manufacturing-related activities for the EB06 program [7]. - General and administrative expenses rose by $0.3 million to $1.2 million for the same period, mainly due to an increase in noncash share-based compensation [7]. Upcoming Events - Edesa plans to participate in several upcoming scientific and medical conferences, including the Global Vitiligo Foundation Annual Scientific Symposium on March 26, 2026, and the American Thoracic Society 2026 International Conference from May 15-20, 2026 [8].